Flexion Therapeutics announced the pricing of its underwritten public offering of 5.04 million shares of common stock at a price to the public of $17 per share.
Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of common stock. BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers.
Flexion Therapeutics is clinical-stage specialty pharmaceutical company focused on the development and commercialization of pain therapies.
More articles on anesthesia:
17 Lincoln Anesthesiology Group providers join The Physician Network
MEDNAX begins $200M accelerated share repurchase
NAPA to provide exclusive anesthesia services at Southington Surgery Center